Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

Moderate Risk

Score: 35/100

Failure Rate

0.0%

0 terminated/withdrawn out of 6 trials

Success Rate

100.0%

+13.5% vs industry average

Late-Stage Pipeline

17%

1 trials in Phase 3/4

Results Transparency

0%

0 of 2 completed trials have results

Key Signals

Enrollment Performance

Analytics

N/A
1(50.0%)
Phase 3
1(50.0%)
2Total
N/A(1)
Phase 3(1)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (6)

Showing 6 of 6 trials
NCT07372261Enrolling By Invitation

Validation of a Prognostic Method for Assessing the Risk of Distant Metastasis in Early-stage Breast Cancer

Role: collaborator

NCT07265414Active Not Recruiting

DRG Mutations in Prostate Cancer: a Guiding Light for Enhanced Screening and Personalised Therapy

Role: collaborator

NCT05160324Not ApplicableUnknown

T1-T2 Breast Cancer: Comparison Between Removal and Preservation of Axillary Lymph Nodes (SINODAR ONE)

Role: lead

NCT02622815Unknown

Hypercoagulation Screening in Cancer

Role: collaborator

NCT00807066Phase 3Completed

Randomized Gefitinib Trial

Role: lead

NCT00587756Completed

Alternative to Two-Stage Hepatectomy

Role: collaborator

All 6 trials loaded